Rivaroxaban, the first oral, direct factor Xa inhibitor

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 18, 2009, Pages 2945-2946

  Fassiadis, Nicholas ^a  

^a St Luke's Hospital   (Greece)

Author keywords

Anticoagulant; Factor Xa Inhibitor; Rivaroxaban

Indexed keywords

ANTIVITAMIN K; ENOXAPARIN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; ELECTIVE SURGERY; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LIVER DYSFUNCTION; LUNG EMBOLISM; POSTOPERATIVE THROMBOSIS; REVIEW; STROKE; SURGICAL RISK; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; FACTOR XA; HUMANS; MORPHOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 71449111698     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903413559     Document Type: Review

References (10)

1. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Throb Haemost 2007;5:2368-2375
2. Borris CL. Rivaroxaban, a new, oral direct factor Xa inhibitor for thromboprohylaxis after major joint arthroplasty. Expert Opin Pharmacother 2009;10:1083-1088
3. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics and pharmacokinetics of single doses of BAY 59 - 7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005;78:412-421
4. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics and pharmacokinetics of single doses of BAY 59 - 7939, an oral, direct factor Xa inhibitor after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-880
5. Graff J, Von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor Rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007;47:1398-1407
6. Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 2006;15:843-855
7. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-2775
8. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; doi:10.1016/ S0140-6736(08)60880-60886
9. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-2786
10. Turpie GA, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomised trial. Lancet 2009;373:1673-1680